Overview of Ongoing and Completed Opioid Related OIG Studies—As of September 30, 2020

I. Prescribing Focused Work

a. Medicare

i. Medicare Part D Payments for Transmucosal Immediate-Release Fentanyl Drugs (W-00-20-35846) Ongoing Audit

ii. Data Brief: Opioid Use in Medicare Part D in 2020 (OEI-02-20-00400) Ongoing Evaluation

iii. Utilization of Medication-Assisted Treatment in Medicare (OEI-02-20-00390) Ongoing Evaluation


v. Toolkit for Calculating Opioid Levels and Identifying Patients At Risk of Misuse or Overdose: R and SQL Programming Code. May 2020 (OEI-02-17-00561)


ix. Data Brief: Concerns About Opioid Use in Medicare Part D in the Appalachian Region. April 2019 (OEI-02-18-00224)


xi. Toolkit: Using Data Analysis To Calculate Opioid Levels and Identify Patients At Risk of Misuse or Overdose. June 2018 (OEI-02-17-00560)

xii. Data Brief: Opioid Use in Medicare Part D: Concerns about Extreme Use and Questionable Prescribing. July 2017 (OEI-02-17-00250)

xiii. Data Brief: High Part D Spending on Opioids and Substantial Growth in Compounded Drugs Raise Concerns. June 2016 (OEI-02-16-00290)


xv. Retail Pharmacies With Questionable Part D Billing. May 2012 (OEI-02-09-00600)

b. Medicaid


c. Other HHS Programs

i. FDA’s Risk Evaluation and Mitigation Strategies: Uncertain Effectiveness in Addressing the Opioid Crisis. September 2020 (OEI-01-17-00510)

ii. Review of Opioid Use in Indian Health Service (OEI-05-18-00470) Ongoing Evaluation

iii. Prescription Opioid Drug Abuse and Misuse Prevention—Prescription Drug Monitoring Programs (W-00-18-59428) Partially Completed Audit Series


v. States’ Use of the Child Welfare Information Systems To Monitor Medication Prescribed to Children in Foster Care (W-00-18-59434) Ongoing Audit


II. Treatment Focused Work
   a. Medicaid
      i. CMS Should Pursue Strategies To Increase the Number of At Risk Beneficiaries Acquiring Naloxone Through Medicaid. September 2020 (OEI-BL-18-00360)
      ii. Review of Medicaid Claims for Opioid Treatment Program Services (W-00-17-31523) Partially Completed Audit Series
          1. New York Claimed Tens of Millions of Dollars for Opioid Treatment Program Services That Did Not Comply With Medicaid Requirements Intended To Ensure the Quality Of Care Provided to Beneficiaries. February 2020 (A-02-17-01021)
      iii. Provider Shortages and Limited Availability of Behavioral Health Services in New Mexico’s Medicaid Managed Care. September 2019 (OEI-02-17-00490)

   b. Other HHS Programs
      i. Data Snapshot: MAT from Providers Waivered at the Highest Patient-Limit Level (OEI-BL-20-00260), Ongoing Evaluation
      v. Opioid Treatment Program Experiences During the COVID-19 Pandemic (W-00-20-59447) Ongoing Audit
      vi. SAMHSA’s Oversight of Accreditation Bodies for Opioid Treatment Programs (W-00-18-59035) Partially Completed Audit Series
          1. SAMHSA’s Oversight of Accreditation Bodies for Opioid Treatment Programs Did Not Comply With Some Federal Requirements. March 2020 (A-09-18-01007)
      vii. HRSA’s Monitoring Did Not Always Ensure Health Centers’ Compliance with Federal Requirements for HRSA’s Access Increases in Mental Health and Substance Abuse Services Supplemental Grant Funding. July 2020 (A-02-18-02010)
      viii. Projects for Assistance in Transition from Homelessness Program (W-00-19-50100) Ongoing Audit
      ix. Access Increases in Mental Health and Substance Abuse Services Funding for Health Centers (W-00-19-59442) Ongoing Audit
x. Post-Award State or Tribal Audits of Substance Abuse and Mental Health Services Administration's Opioid Response Grants.  (W-00-20-59441) Ongoing Audit Series

xi. SAMHSA Followed Grant Regulations and Program-Specific Requirements When Awarding State Targeted Response to the Opioid Crisis Grants. March 2019 (A-03-17-03302)

xii. New York Did Not Provide Adequate Stewardship of Substance Abuse Prevention and Treatment Block Grant Funds. March 2019 (A-02-17-02009)

### III. Work Focused on Both Treatment and Prescribing

#### a. Review of States’ Oversight of Opioid Prescribing and Monitoring of Opioid Use (W-00-18-59440) Partially Completed Audit Series


#### b. Services for American Indians and Alaska Natives Administered by a Federally Qualified Health Center (W-00-17-59052)

i. The Penobscot Indian Nation Did Not Meet All Federal and Tribal Health and Safety Requirements. November 2018 (A-01-17-01502)

ii. The Passamaquoddy Tribe's Pleasant Point Health Center Did Not Always Meet Federal and Tribal Health and Safety Requirements. July 2018 (A-01-17-01500)


For more detail on OIG’s opioid work, visit:

https://oig.hhs.gov/reports-and-publications/featured-topics/opioids/